LONDON, March 30 (Reuters) - Britain's healthcare cost watchdog NICE has r
ecommended against using Bristol-Myers Squibb's rheumatoid arthritis drug Orencia on the state health service as a second-line treatment.
The National Institute for Health and Clinical Excellence (NICE) said on Wednesday it did not support giving the biotech drug to rheumatoid arthritis patients whose disease has responded inadequately to conventional non-biological medicines.
NICE already recommends four other biotech drugs for such second-line use.
Orencia is among a selection of medicines that can be considered later on if patients fail to respond adequately to one of a class of biological therapies known as tumour necrosis factor (TNF) inhibitors.
The latest draft guidance on Orencia's second-line use is subject to consultation.
NICE's decisions are often watched by governments around the world who increasingly have to weigh the benefits of modern medicines against their price. Orencia costs around 10,000 pounds ($16,000) per patient a year.
(Reporting by Ben Hirschler; Editing by Mike Nesbit)
COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.